argenx SE Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus Transcript

Dec 20, 2023 / 01:30PM GMT
Operator

Hello, and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. (Operator Instructions)

I would now like to turn the conference over to Beth DelGiacco, Vice President of Corporate Communications and Investor Relations. Please go ahead.

Beth DelGiacco Argenx SE-VP of Corporate Communications&IR

Thank you and to everyone for joining us today. A press release was issued this morning with the top line results from the address study of Efgartigimod SC in Pemphigus. We have a short slide deck to accompany our remarks this morning, which is also available on the Investors section of our website for your reference.

Before we begin, I would like to remind you on slide 2 that forward-looking statements may be presented during this call is may include statements about our future

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot